结直肠癌 (CRC) 仍然是癌症相关死亡率的一个重要因素，这强调了迫切需要确定可以改善临床管理和患者预后的生物标志物。在这项回顾性研究中，我们分析了 25 名转移性 CRC 患者的肿瘤样本，根据长期（> 50 个月）或短期（< 10 个月）生存进行分类。利用包含 770 个基因的 PanCancer Immune Profile Panel，我们在发现数据集中确定了转移性 CRC 肿瘤微环境中的 54 个差异表达基因 (DEG)。使用两个公开的基于 RNA 的测序数据集（TCGA 1 (n=371) 和 TCGA 2 (n=566)）对潜在生物标志物进行验证。单变量 COX 回归揭示了发现数据集中三个重要的生物标志物与 CRC 的总体生存率相关，它们是 SLC11A1（风险比 (HR)：4.09，P=0.012）、TNFSF11（HR：3.67，P=0.02）和 MEF2C （HR：0.34，P=0.037）。 Kaplan-Meier 生存曲线分析证实了发现集 (P=0.0071) 和两个独立数据集（TCGA 1 (P=0.0016) 和 TCGA 2 (P=0.025)）中 SLC11A1 表达与 CRC 总体生存率之间的相关性。受试者工作特征曲线分析显示，曲线下面积范围为 0.64 至 0.76，预测 CRC 总生存期的敏感性为 59% 至 87%，特异性为 60% 至 73%。免疫组织化学染色进一步验证了SLC11A1蛋白在CRC肿瘤细胞中的强表达，高表达与短期存活相关。这些发现表明 SLC11A1 可作为 CRC 患者总生存期的预测生物标志物。AJCR 版权所有 © 2024。

Colorectal cancer (CRC) remains a significant contributor to cancer-related mortality, emphasizing the critical need for identifying biomarkers that can improve clinical management and patient outcomes. In this retrospective study, we analyzed tumor samples from 25 patients with metastatic CRC, categorized based on long-term (> 50 months) or short-term (< 10 months) survival. Employing the PanCancer Immune Profile Panel, encompassing 770 genes, in the discovery dataset, we identified 54 differentially expressed genes (DEGs) within the tumor microenvironment of metastatic CRC. Validation of potential biomarkers was performed using two publicly available RNA-based sequencing datasets (TCGA 1 (n=371) and TCGA 2 (n=566)). Univariate COX regression unveiled that three significant biomarkers were associated with overall survival in CRC within the discovery dataset, which were SLC11A1 (hazard ratio (HR): 4.09, P=0.012), TNFSF11 (HR: 3.67, P=0.02), and MEF2C (HR: 0.34, P=0.037). Kaplan-Meier survival curve analyses confirmed the correlation between SLC11A1 expression and overall survival in CRC across the discovery set (P=0.0071) and the two independent datasets (TCGA 1 (P=0.0016) and TCGA 2 (P=0.025)). Receiver operating characteristic curve analysis demonstrated an area under the curve ranging from 0.64 to 0.76, with sensitivity of 59% to 87% and specificity of 60% to 73% for predicting CRC overall survival. Immunohistochemistry staining further validated the strong expression of SLC11A1 protein in CRC tumor cells, with high expression correlating with short-term survival. These findings suggest that SLC11A1 serves as a predictive biomarker for overall survival in CRC patients.AJCR Copyright © 2024.